Pancreatic Serous Cystadenoma: CT & MRI Imaging, Diagnosis, Treatment, and Prognosis
Serous Cystadenoma of the Pancreas: Complete Guide to Pathophysiology, Imaging, Diagnosis, Treatment, and Prognosis
Serous cystadenoma of the pancreas, also called pancreatic serous cystadenoma (SCA) or serous cystic neoplasm (SCN), is one of the most important benign pancreatic cystic tumors to recognize on CT and MRI.
For patients, the diagnosis can sound frightening because the word “neoplasm” means a new growth or tumor. However, pancreatic serous cystadenoma is fundamentally different from pancreatic ductal adenocarcinoma and from pancreatic cystic tumors such as mucinous cystic neoplasm (MCN) and intraductal papillary mucinous neoplasm (IPMN), which have substantially different malignant potential.
The classic pancreatic serous cystadenoma is a benign, glycogen-rich epithelial tumor, often composed of numerous tiny cysts that create a characteristic microcystic or honeycomb appearance. A central fibrous scar, sometimes with calcification, can be another highly useful imaging clue.
The case presented in the attached material is particularly instructive: a woman in her 60s underwent CT and MRI evaluation of a pancreatic mass, and the imaging demonstrated a well-defined, multiloculated cystic lesion in the pancreatic tail with multiple thin septa and a central low-signal scar.
This article provides a comprehensive, evidence-based review of serous cystadenoma of the pancreas, including its pathophysiology, molecular biology, epidemiology, clinical presentation, CT findings, MRI findings, differential diagnosis, diagnosis, treatment, surveillance, and prognosis.
Why Is Serous Cystadenoma of the Pancreas Important?
Pancreatic cystic lesions are increasingly detected because CT and MRI are performed far more frequently than in the past. Contemporary population studies suggest that pancreatic cystic lesions are common, with prevalence increasing substantially with age. A 2026 review noted prevalence estimates ranging from approximately 13% to nearly 50%, depending on the population and imaging modality.
This creates an important clinical problem.
Not every pancreatic cyst is dangerous.
Some lesions are:
Completely benign
Premalignant
Potentially malignant
Already malignant
Non-neoplastic, such as pseudocysts
The clinical challenge is therefore not simply to detect a pancreatic cyst. It is to determine what type of pancreatic cystic lesion is present and whether the patient actually benefits from surgery or surveillance.
Serous cystadenoma is particularly important because it is generally benign, yet it can resemble other pancreatic cystic neoplasms on imaging.
Correct recognition can therefore prevent unnecessary pancreatic surgery.
1. What Is Serous Cystadenoma of the Pancreas?
Serous cystadenoma is a benign epithelial neoplasm of the pancreas.
The terminology deserves clarification.
The terms serous cystadenoma, serous cystic neoplasm, and serous cystic tumor are frequently encountered in clinical literature. The World Health Organization classification recognizes serous cystadenoma as a benign pancreatic epithelial neoplasm. WHO classification materials describe the lesion as a tumor composed of uniform cuboidal, glycogen-rich cells that frequently form cysts containing serous fluid.
The lesion is sometimes described as a microcystic adenoma because many tumors contain numerous tiny cystic spaces.
A typical serous cystadenoma may therefore look almost like a sponge or honeycomb on cross-sectional imaging.
The major radiologic concept is:
microcystic architecture + thin enhancing septa + central scar = classic serous cystadenoma pattern
However, not every serous cystadenoma has the classic appearance.
There are several morphologic variants, including:
Microcystic serous cystadenoma
Macrocystic or oligocystic serous neoplasm
Solid serous neoplasm
VHL-associated serous cystic neoplasms
Rare mixed serous-neuroendocrine lesions
The less typical forms are more difficult to distinguish from other pancreatic cystic tumors.
2. Pathophysiology and Molecular Biology
A Benign Glycogen-Rich Epithelial Tumor
The microscopic hallmark of pancreatic serous cystadenoma is the presence of relatively uniform cuboidal epithelial cells containing abundant glycogen.
The cells line the cystic spaces and are associated with a prominent capillary network.
Unlike mucinous pancreatic tumors, serous cystadenoma does not primarily represent a mucin-producing neoplastic process.
This biological distinction explains many of the imaging and laboratory differences between serous cystadenoma and mucinous cystic neoplasms.
The VHL Pathway
One of the most important molecular associations is the von Hippel–Lindau (VHL) pathway.
Molecular studies have demonstrated that pancreatic serous tumors can harbor alterations involving the VHL pathway. Serous pancreatic tumors share biological characteristics with other glycogen-rich clear-cell tumors associated with VHL signaling.
This relationship is especially important in patients with von Hippel–Lindau syndrome.
Patients with VHL syndrome can develop:
Multiple pancreatic cysts
Serous cystic neoplasms
Renal cell carcinoma
Pancreatic neuroendocrine tumors
Other VHL-associated tumors
Therefore, multiple pancreatic serous lesions, particularly in a younger patient or a patient with other VHL-associated manifestations, should prompt consideration of a syndromic process.
3. Epidemiology
Serous cystadenoma has a characteristic demographic profile.
It occurs predominantly in:
Older adults
Women
Patients without a strong history of pancreatitis
Patients in whom the lesion is discovered incidentally
The large multinational study of 2,622 pancreatic serous cystic neoplasms reported that 74% of patients were women and that the median age at diagnosis was 58 years. Importantly, 61% of patients were asymptomatic at presentation.
This is highly consistent with the attached case, which describes a woman in her 60s undergoing evaluation of a pancreatic mass.
Serous cystadenoma is therefore sometimes informally referred to as the “grandmother lesion” because of its strong association with older women.
That nickname is useful for memory, but it should not be used as a diagnostic criterion.
4. Clinical Presentation
Most Patients Are Asymptomatic
The majority of pancreatic serous cystadenomas are discovered incidentally.
A patient may undergo:
Abdominal CT
MRI
MRCP
Ultrasound
Imaging for unrelated abdominal symptoms
and the pancreatic cystic lesion is discovered unexpectedly.
In the large multinational study, 61% of patients were asymptomatic. When symptoms occurred, nonspecific abdominal pain was the most common symptom.
Symptoms When They Occur
Large serous cystadenomas can cause symptoms through mass effect.
Potential symptoms include:
Upper abdominal discomfort
Abdominal pain
Early satiety
Nausea
Vomiting
Gastric outlet symptoms
Biliary obstruction
Pancreatic duct obstruction
Rare vascular compression
A lesion in the pancreatic head may compress the common bile duct and cause obstructive jaundice.
A large lesion in the body or tail may compress the stomach or adjacent structures.
Importantly, symptoms do not necessarily indicate malignant transformation.
In serous cystadenoma, symptoms are often related to size and anatomic compression, not cancer.
5. Imaging Features of Pancreatic Serous Cystadenoma
Imaging is the most important component of the diagnosis.
The major modalities are:
Contrast-enhanced CT
MRI
MRCP
Endoscopic ultrasound (EUS)
Modern reviews emphasize the continuing central role of high-resolution CT and MRI/MRCP for characterization of pancreatic cystic lesions.
6. CT Findings of Serous Cystadenoma
The classic CT appearance is a:
well-circumscribed, multiloculated, microcystic pancreatic mass with numerous thin septa.
The lesion may have a characteristic honeycomb or sponge-like architecture.
The cystic spaces can be extremely small and may be difficult to appreciate on lower-resolution imaging.
Classic CT features include:
Well-defined margins
Multiloculated appearance
Numerous small cystic spaces
Thin internal septa
Enhancement of the septa
Central scar
Possible central calcification
No pancreatic duct communication in most cases
Usually no marked pancreatic duct dilation
The attached CT case demonstrates a complex multiloculated cystic mass in the pancreatic tail containing multiple thin septa, with no reported pancreatic duct dilation.
This is a highly characteristic pattern for serous cystadenoma.
7. The Central Scar
The central scar is one of the most memorable imaging findings.
A central scar is usually composed of fibrous tissue and may demonstrate:
Low signal intensity on T2-weighted MRI
Delayed enhancement
Central calcification on CT
When calcification is present, it may produce a characteristic central sunburst-type pattern.
However, the absence of a central scar does not exclude serous cystadenoma.
The attached MRI case specifically describes a central T2-low-signal component suggesting a central scar.
8. MRI and MRCP Findings
MRI is particularly useful for characterizing pancreatic cystic lesions.
The major advantages of MRI include:
Excellent soft-tissue contrast
Superior demonstration of small cystic components
Evaluation of septa
Identification of mural nodules
Assessment of the pancreatic duct
MRCP evaluation of communication with the ductal system
The classic MRI appearance of serous cystadenoma is a multiloculated lesion containing numerous small cystic spaces.
On T2-weighted imaging, the cystic spaces are typically very bright.
The fibrous central scar can appear relatively dark on T2-weighted sequences.
The attached case includes axial T2-weighted MRCP imaging and demonstrates the characteristic multicystic pancreatic-tail architecture.
9. Contrast Enhancement
Another important clue is enhancement of the internal septa.
The cystic fluid itself generally does not enhance.
Instead, the thin septa may demonstrate enhancement following intravenous contrast.
The attached MRI report describes:
“thin septa” with mild enhancement
and a central T2-low-signal component suggesting a scar.
This combination is strongly supportive of a serous cystic neoplasm.
10. Diffusion-Weighted Imaging and ADC
The supplied case also includes diffusion-weighted imaging (DWI) and an apparent diffusion coefficient (ADC) map.
These sequences can contribute to the overall MRI assessment of a pancreatic cystic lesion.
However, DWI should not be interpreted in isolation.
The diagnosis of serous cystadenoma depends primarily on:
Morphology
Microcystic architecture
Septal characteristics
Enhancement pattern
Central scar
Relationship to the pancreatic duct
Clinical context
DWI and ADC are supportive rather than pathognomonic.
The source document identifies this imaging panel as DWI and ADC.
11. Differential Diagnosis of Serous Cystadenoma
The most important differential diagnoses are:
Mucinous cystic neoplasm
Branch-duct IPMN
Cystic pancreatic neuroendocrine tumor
Pancreatic pseudocyst
Solid pseudopapillary neoplasm
Cystic degeneration of other pancreatic tumors
Rare cystic lesions
Serous Cystadenoma vs. Mucinous Cystic Neoplasm
This is one of the most important distinctions.
Serous cystadenoma
Typically:
Older woman
Microcystic
Honeycomb appearance
Thin septa
Central scar
Usually no duct communication
Very low malignant potential
Mucinous cystic neoplasm
Typically:
Middle-aged or older woman
Body or tail
Macrocystic or oligocystic
Often unilocular or few large cysts
Ovarian-type stroma histologically
Potential malignant transformation
This distinction matters because MCN has substantially greater malignant potential and may require surgical management depending on size and high-risk features.
12. Serous Cystadenoma vs. IPMN
IPMN is another major differential diagnosis.
A key feature of IPMN is communication with the pancreatic ductal system.
MRCP is particularly useful for evaluating this relationship.
IPMN may show:
Main pancreatic duct dilation
Branch duct cystic lesions
Mucin
Intraductal nodules
Multifocal disease
In contrast, a typical serous cystadenoma is a discrete parenchymal cystic mass without ductal communication.
The absence of pancreatic duct dilation in the attached case therefore supports the diagnosis of serous cystadenoma.
13. Serous Cystadenoma vs. Pancreatic Neuroendocrine Tumor
A cystic pancreatic neuroendocrine tumor may contain:
Solid enhancing components
Peripheral hyperenhancement
Necrotic areas
Vascularity
The distinction can sometimes be difficult.
A serous cystadenoma typically has a characteristic microcystic architecture, whereas a cystic neuroendocrine tumor often has a more solid enhancing component.
European guidelines emphasize that cystic pancreatic neuroendocrine tumors and serous cystic neoplasms can occasionally overlap in appearance.
14. Serous Cystadenoma vs. Pancreatic Pseudocyst
A pancreatic pseudocyst is not a true neoplasm.
It typically develops in the setting of:
Acute pancreatitis
Chronic pancreatitis
Pancreatic trauma
Clinical history is therefore extremely important.
A patient with no history of pancreatitis and a classic microcystic pancreatic lesion should raise suspicion for serous cystadenoma rather than pseudocyst.
15. Diagnosis of Serous Cystadenoma
The diagnosis is often made radiologically.
This is one of the major practical advantages of recognizing the classic imaging pattern.
When CT and MRI demonstrate:
microcystic architecture + thin enhancing septa + central scar + no ductal dilation
the diagnosis can often be made with high confidence.
The attached case explicitly emphasizes that serous cystadenoma can often be diagnosed using imaging without biopsy.
However, “often” does not mean “always.”
Atypical lesions may require additional evaluation.
16. When Is Endoscopic Ultrasound Useful?
Endoscopic ultrasound (EUS) is particularly useful when the imaging diagnosis is uncertain.
EUS can provide:
High-resolution morphology
Evaluation of septa
Assessment of mural nodules
Evaluation of solid components
Cyst fluid sampling
Cytology
Biochemical testing
Molecular testing in selected centers
However, even EUS morphology is not perfect.
A 2023 study of pathologically confirmed serous cystic neoplasms found that CT/MRI and EUS did not always provide a correct preoperative diagnosis, illustrating why atypical cases can be challenging. The same study found that selected cyst-fluid biomarkers performed substantially better in difficult cases.
17. Cyst Fluid Analysis
When diagnosis remains uncertain, cyst fluid can provide additional information.
Traditional cyst-fluid testing may include:
CEA
Amylase
Cytology
More recently, additional biomarkers have attracted attention.
For example:
Glucose
VEGF-A
Molecular alterations
KRAS
GNAS
VHL-related alterations
Low cyst-fluid CEA tends to support a nonmucinous lesion, while cyst-fluid glucose can help differentiate mucinous from nonmucinous cysts.
VEGF-A is particularly interesting in serous cystic neoplasms because of the prominent vascular biology associated with these tumors. Studies have reported high diagnostic performance when VEGF-A is combined with CEA in selected settings.
A 2024 review emphasizes that no single cyst-fluid biomarker currently solves every pancreatic cyst diagnostic problem, and biomarker testing should be interpreted in the context of imaging and clinical findings.
18. Treatment of Serous Cystadenoma
The central treatment principle is:
Do Not Automatically Operate on a Benign Pancreatic Cyst
If the diagnosis of serous cystadenoma is secure and the patient is asymptomatic, observation is usually preferred over pancreatic resection.
This is extremely important because pancreatic surgery is not trivial.
Depending on tumor location, surgery may involve:
Distal pancreatectomy
Pancreaticoduodenectomy
Enucleation in selected circumstances
All pancreatic resections carry risks, including:
Postoperative pancreatic fistula
Bleeding
Infection
Delayed gastric emptying
Diabetes
Exocrine pancreatic insufficiency
Long-term nutritional consequences
Therefore, removing a benign pancreatic lesion requires a strong clinical justification.
19. When Should Serous Cystadenoma Be Resected?
Surgery may be considered when:
The diagnosis remains uncertain
The lesion causes significant symptoms
There is substantial compression of adjacent organs
There is rapid growth
There are atypical or suspicious features
There is clinically significant obstruction
The lesion is large and increasingly symptomatic
European evidence-based guidelines state that when the diagnosis of serous cystic neoplasm is clear, surgery is primarily recommended for patients with symptoms related to compression of adjacent structures.
Importantly, size alone should not automatically trigger surgery.
Some older surgical literature used thresholds such as 4 cm, particularly when considering the likelihood of symptoms and growth. Modern management is more individualized.
20. What Does Recent Natural-History Research Show?
A large multinational study of 2,622 patients demonstrated the generally indolent behavior of serous cystic neoplasms.
Among patients followed for more than one year:
37% increased in size
57% remained stable
6% decreased
The average growth rate was approximately 4 mm/year
Only three serous cystadenocarcinomas were recorded, and disease-specific mortality was extremely low.
More recent natural-history research involving 203 patients also supports the concept that pancreatic serous cystic neoplasms generally behave slowly, while providing a model for identifying unusually fast-growing lesions.
This supports a conservative management philosophy in appropriately selected patients.
21. Prognosis
The prognosis of pancreatic serous cystadenoma is excellent.
The tumor is generally considered benign.
The major concern is not usually malignant transformation but rather:
diagnostic uncertainty + tumor growth + mass effect
The European evidence-based guideline considers serous cystic neoplasm a benign entity and notes that disease-specific mortality attributable to malignant behavior is nearly zero.
The attached case similarly states that the probability of malignant progression is extremely low and that observation is generally appropriate when the lesion is asymptomatic.
22. Surveillance: Does Every Patient Need Long-Term MRI?
This is an area in which guidelines and clinical practices have evolved.
If imaging establishes a confident diagnosis of serous cystadenoma, prolonged oncologic surveillance is generally not necessary in the same way it is for a potentially premalignant IPMN.
The European guidelines recommend follow-up for one year in asymptomatic patients with radiologically established SCN, followed thereafter by symptom-based follow-up. If the diagnosis remains uncertain, more intensive surveillance is recommended because the lesion might actually represent another cystic neoplasm.
Updated clinical summaries similarly emphasize that confirmed asymptomatic SCNs generally do not require indefinite routine imaging, while uncertainty, large size, growth, symptoms, or VHL-associated disease may justify continued monitoring.
The key principle is therefore:
Surveillance intensity should reflect diagnostic certainty and clinical risk—not simply the presence of a pancreatic cyst.
23. The Case: Detailed Imaging Interpretation
The uploaded case concerns a woman in her 60s who underwent CT and MRI to characterize a pancreatic mass.
The CT examination demonstrates a multiloculated cystic mass in the pancreatic tail with multiple thin septa. No pancreatic duct dilation is reported.
MRI further demonstrates a well-defined multicystic pancreatic-tail lesion with thin septa and a central low-signal component suggesting a central scar. The septa show mild enhancement, while no biliary dilation or other concerning imaging features are reported.
This is a classic teaching case for pancreatic serous cystadenoma.
24. Axial Contrast-Enhanced CT, Portal Venous Phase
Figure 1. Axial contrast-enhanced CT, portal venous phase.
Imaging interpretation: The image demonstrates a complex, multiloculated cystic lesion involving the pancreatic tail. Multiple thin internal septa are present. The overall architecture is compatible with a microcystic serous cystic neoplasm. The source case reports no pancreatic duct dilation.
Teaching point: A multiloculated pancreatic lesion containing numerous small cystic spaces should immediately raise the possibility of serous cystadenoma, particularly in an older woman.
25. Coronal Contrast-Enhanced CT, Portal Venous Phase
Figure 2. Coronal contrast-enhanced CT, portal venous phase.
Imaging interpretation: Coronal imaging confirms the well-defined cystic mass in the pancreatic tail and demonstrates its multiloculated architecture. The lesion contains numerous thin septa, supporting the diagnosis of pancreatic serous cystadenoma.
Teaching point: Multiplanar CT reconstruction is valuable because the relationship of a pancreatic cystic lesion to the pancreatic parenchyma and adjacent organs becomes easier to appreciate.
26. Sagittal Contrast-Enhanced CT, Portal Venous Phase
Figure 3. Sagittal contrast-enhanced CT, portal venous phase.
Imaging interpretation: Sagittal CT further demonstrates the multiloculated cystic architecture of the pancreatic tail mass. The lesion remains well-defined without the reported pancreatic duct dilation or other major worrisome features.
Teaching point: The combination of morphology, patient demographics, and absence of ductal obstruction is more informative than any single imaging feature.
27. Axial T2-Weighted MRCP
Figure 4. Axial T2-weighted MRCP.
Imaging interpretation: The lesion demonstrates numerous small fluid-containing cystic spaces. A central low-signal fibrous component is compatible with a central scar, an important classic feature of pancreatic serous cystadenoma.
Teaching point: MRI can demonstrate the microcystic architecture more clearly than CT in some patients and is particularly useful for evaluating ductal anatomy.
28. Axial T1-Weighted Contrast-Enhanced Fat-Suppressed MRI
Figure 5. Axial T1-weighted contrast-enhanced fat-suppressed MRI, portal venous phase.
Imaging interpretation: Thin internal septa demonstrate mild enhancement. The cystic components themselves remain nonenhancing. The overall pattern supports a multiloculated serous cystic neoplasm.
Teaching point: Enhancement of thin septa is compatible with the vascularized stromal architecture of serous cystadenoma.
29. Axial T1-Weighted Delayed Post-Contrast MRI
Figure 6. Axial T1-weighted contrast-enhanced fat-suppressed MRI, 2-minute delayed phase.
Imaging interpretation: The delayed phase provides additional information about enhancement of the internal septal and stromal components. The overall microcystic morphology remains characteristic of the pancreatic tail serous cystic neoplasm.
Teaching point: Dynamic contrast-enhanced MRI can improve confidence when the lesion's internal architecture is complex.
30. Diffusion-Weighted Imaging and ADC Map
Figure 7. Diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) map.
Imaging interpretation: The supplied case includes DWI and ADC imaging as part of the MRI assessment of the pancreatic lesion. These sequences should be interpreted in conjunction with morphology, T1/T2 signal, contrast enhancement, and MRCP findings rather than as a standalone diagnostic test.
Teaching point: Advanced MRI sequences are complementary. The diagnosis of serous cystadenoma remains primarily a morphologic and multimodality imaging diagnosis.
31. Three Medical Knowledge Questions for Readers
Question 1: Which Imaging Pattern Is Most Characteristic?
A 67-year-old woman undergoes abdominal CT for unrelated abdominal symptoms. Imaging reveals a well-circumscribed pancreatic body/tail lesion containing numerous tiny cystic spaces separated by thin enhancing septa. A central fibrous scar is present, and there is no pancreatic duct dilation.
Which diagnosis is most likely?
A. Pancreatic pseudocyst
B. Mucinous cystic neoplasm
C. Serous cystadenoma of the pancreas
D. Main-duct IPMN
E. Pancreatic ductal adenocarcinoma
Correct Answer: C. Serous cystadenoma of the pancreas
Explanation
The combination of older age, female sex, microcystic or honeycomb architecture, thin enhancing septa, central scar, and lack of pancreatic duct dilation strongly favors serous cystadenoma.
Mucinous cystic neoplasms tend to be more macrocystic and have different biological behavior. IPMN is characterized by ductal communication or ductal involvement. Pancreatic ductal adenocarcinoma usually produces a solid infiltrative mass rather than a classic microcystic lesion.
Question 2: What Is the Most Appropriate Management?
A 64-year-old woman has a pancreatic lesion with highly characteristic imaging findings of serous cystadenoma. She has no abdominal pain, no jaundice, no pancreatic duct obstruction, and no evidence of invasive disease.
What is the most appropriate management strategy?
A. Immediate pancreaticoduodenectomy
B. Immediate distal pancreatectomy regardless of tumor location
C. Conservative management with appropriate clinical/imaging follow-up
D. Chemotherapy
E. Radiation therapy
Correct Answer: C. Conservative management with appropriate clinical/imaging follow-up
Explanation
Serous cystadenoma is a benign pancreatic neoplasm with extremely low malignant potential. When the diagnosis is secure and the patient is asymptomatic, pancreatic resection generally exposes the patient to unnecessary operative risk.
European evidence-based guidelines recommend conservative management for clearly diagnosed asymptomatic SCN, with surgery primarily reserved for symptomatic lesions causing compression or cases in which the diagnosis remains uncertain.
Question 3: Which Feature Most Strongly Favors Serous Cystadenoma Over IPMN?
A pancreatic cystic lesion is found on MRI. Which finding most strongly supports serous cystadenoma rather than branch-duct IPMN?
A. Communication with the pancreatic duct
B. Main pancreatic duct dilation
C. Numerous tiny cysts producing a honeycomb appearance with thin enhancing septa
D. Mucin extrusion through the ampulla
E. Diffuse main duct involvement
Correct Answer: C. Numerous tiny cysts producing a honeycomb appearance with thin enhancing septa
Explanation
The microcystic/honeycomb pattern with thin septal enhancement is a classic imaging clue for serous cystadenoma.
By contrast, ductal communication and main pancreatic duct abnormalities favor IPMN.
MRCP is particularly useful when the key diagnostic question is whether the cystic lesion communicates with the pancreatic ductal system.
32. A Simple Radiology Memory Rule
For medical students, residents, and physicians, this mnemonic is useful:
“SEROUS = Sponge-like, Elderly, Radiologically distinctive, Usually benign, Scar”
S — Sponge-like microcystic architecture
E — Elderly patient, often a woman
R — Radiologic diagnosis is often possible
O — Usually benign
U — Usually observed when asymptomatic
S — Scar may be present centrally
This is not a substitute for formal diagnosis, but it is a useful examination memory aid.
33. The Most Important Clinical Message
The most important lesson from pancreatic serous cystadenoma is not simply how to recognize the tumor.
It is understanding when not to operate.
Pancreatic surgery can be life-saving when it is indicated. But pancreatic surgery also carries meaningful morbidity.
Therefore, a benign pancreatic lesion should not automatically be removed simply because it is large, complex, or described as a “tumor.”
The clinician must first determine:
Is the diagnosis secure?
Is the patient symptomatic?
Is the lesion growing rapidly?
Is there compression of adjacent organs?
Are there atypical imaging features?
Could the lesion actually be a mucinous or malignant neoplasm?
Would surgery provide a meaningful clinical benefit?
Modern management is increasingly focused on risk-adapted decision-making rather than automatic resection.
34. Final Take-Home Points
Serous Cystadenoma of the Pancreas: 10 Essential Facts
1. Pancreatic serous cystadenoma is a benign epithelial neoplasm.
2. It occurs predominantly in older women.
3. Most patients are asymptomatic, and the lesion is discovered incidentally.
4. The classic CT finding is a multiloculated microcystic or honeycomb pancreatic mass.
5. Thin enhancing septa are a characteristic imaging feature.
6. A central fibrous scar, sometimes with calcification, is an important diagnostic clue.
7. MRI and MRCP are valuable for lesion characterization and evaluation of ductal anatomy.
8. The major differential diagnoses include MCN, IPMN, cystic neuroendocrine tumor, and pseudocyst.
9. EUS and cyst-fluid analysis are most useful when imaging is indeterminate.
10. A confidently diagnosed asymptomatic serous cystadenoma is usually managed conservatively rather than with pancreatic surgery.
The attached case is an excellent example of this classic imaging pattern: a well-defined multicystic pancreatic-tail lesion containing thin septa and a central scar, without pancreatic duct dilation or other major concerning features.
35. Frequently Asked Questions About Pancreatic Serous Cystadenoma
Is pancreatic serous cystadenoma cancer?
Usually, no. Serous cystadenoma is considered a benign pancreatic neoplasm. Modern international guidance considers its malignant potential extremely low.
Can pancreatic serous cystadenoma become cancer?
True malignant serous neoplasms are exceptionally rare. The large multinational study of 2,622 patients recorded only three serous cystadenocarcinomas and extremely low disease-specific mortality.
Does serous cystadenoma require surgery?
Not usually. Surgery is generally reserved for symptomatic lesions, significant mass effect, diagnostic uncertainty, or selected atypical/rapidly enlarging lesions.
What does serous cystadenoma look like on CT?
The classic appearance is a well-circumscribed, multiloculated, microcystic pancreatic mass with thin enhancing septa. A central scar and central calcification may also be present.
What does serous cystadenoma look like on MRI?
MRI often shows a T2-bright microcystic lesion with multiple thin septa. A central fibrous scar can appear relatively T2 dark. MRCP helps evaluate the relationship between the lesion and the pancreatic duct.
Is serous cystadenoma more common in women?
Yes. Large clinical series demonstrate a strong female predominance. In the international study of 2,622 patients, 74% were women.
What is the difference between serous cystadenoma and mucinous cystic neoplasm?
Serous cystadenoma is generally benign and characteristically microcystic. Mucinous cystic neoplasm has malignant potential and is typically macrocystic/oligocystic, often occurring in the pancreatic body or tail of women.
Is MRI better than CT for pancreatic cysts?
MRI/MRCP provides excellent soft-tissue and ductal characterization, while CT is highly useful for overall morphology, calcification, enhancement, and staging. In practice, the two modalities are complementary.
References
[1] European Study Group on Cystic Tumours of the Pancreas, “European evidence-based guidelines on pancreatic cystic neoplasms,” Gut, vol. 67, no. 5, pp. 789–804, 2018, doi: 10.1136/gutjnl-2018-316027.
[2] B. Jais et al., “Serous cystic neoplasm of the pancreas: A multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club,” Gut, vol. 65, no. 2, pp. 305–312, 2016, doi: 10.1136/gutjnl-2015-309638.
[3] G. H. Elta, B. K. Enestvedt, B. G. Sauer, and A. M. Lennon, “ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts,” American Journal of Gastroenterology, vol. 113, no. 4, pp. 464–479, 2018, doi: 10.1038/ajg.2018.14.
[4] O. Alwahbi, Z. Ghumman, C. B. van der Pol, M. N. Patlas, and P. Gopee-Ramanan, “Pancreatic cystic lesions: Review of the current state of diagnosis and surveillance,” Canadian Association of Radiologists Journal, vol. 74, no. 3, pp. 557–569, 2023, doi: 10.1177/08465371221130524.
[5] Z. F. Rahmatullah, I. Yazdani Nia, E. Afghani, and A. Zaheer, “Exploring the new Kyoto guidelines for managing pancreatic cysts: An overview and comparison with previous guidelines,” Abdominal Radiology, vol. 50, no. 6, pp. 2660–2675, 2025, doi: 10.1007/s00261-024-04665-2.
[6] T. Pollini, L. Todeschini, and A. V. Maker, “Pancreas cyst diagnosis and advances in cyst fluid analysis,” Surgical Clinics of North America, vol. 104, no. 5, pp. 965–974, 2024, doi: 10.1016/j.suc.2024.03.003.
[7] T. Oh et al., “Natural history and growth prediction model of pancreatic serous cystic neoplasms,” 2024.
[8] S. R. Nikolic, R. Pellegrini, M. Del Chiaro, and G. Capurso, “Epidemiology, classification and clinical burden of pancreatic cystic lesions,” Best Practice & Research Clinical Gastroenterology, vol. 81, p. 102074, 2026, doi: 10.1016/j.bpg.2025.102074.
[9] N. Shumka and P. I. Karagyozov, “Cystic tumors of the pancreas: Current perspectives on diagnosis and management,” World Journal of Gastroenterology, vol. 31, no. 43, p. 111393, 2025, doi: 10.3748/wjg.v31.i43.111393.
[10] C. B. Lennon et al., “Pancreatic cystic neoplasms: A review of current recommendations for surveillance and management,” Abdominal Radiology, 2021, doi: 10.1007/s00261-021-03030-x.
[11] S. M. Lee et al., “Serous cystic neoplasms of the pancreas: Clinicopathologic and molecular characteristics,” Seminars in Diagnostic Pathology, 2014.
[12] A. K. Singh et al., “Serous neoplasms of the pancreas: A clinicopathologic analysis of 193 cases and literature review with new insights on macrocystic and solid variants,” American Journal of Surgical Pathology, vol. 39, 2015, doi: 10.1097/PAS.0000000000000559.
Medical Disclaimer
This article is intended for medical education and general information. It does not replace an individualized evaluation by a radiologist, gastroenterologist, pancreatic surgeon, or other qualified healthcare professional. Management of a pancreatic cystic lesion should be based on the patient's clinical history, imaging findings, diagnostic certainty, surgical fitness, and multidisciplinary assessment.
Comments
Post a Comment